Company: IMRX
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001790340-25-000061
Chunk: 374

Company: Immuneering Corp
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 8
Chunk 374
---
 makes such decisions based on consolidated net loss. This measure is used to monitor budget versus actual results to evaluate the performance of the segment. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to deploy these resources across functions and operations (including research and development) that align with the Company’s strategic goals. All of the Company’s long-lived assets are held in the United States.The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment.Three Months Ended March 31,20252024Program expenses(1)IMM-1-104$4,257,936 $3,646,159 IMM-6-4151,623,755 1,027,570 Other programs1,242,109 2,050,612 Non-program expenses(2)1,204,385 1,307,366 Employee-related costs5,378,938 5,729,077 Stock-based compensation expense1,692,267 1,474,758 Depreciation and amortization85,261 90,208 Other segment items(3)(438,519)(1,017,921)Net loss$15,046,132 $14,307,829 (1) Includes direct research and development expenses.(2) Includes general and administrative expenses, in addition to facilities and other research and development expenses.(3) Includes interest income and other (income) expense.

21

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our interim condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and with our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, including the audited consolidated financial statements and notes thereto. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview